Study Title

fusionpharmaceuticalsinc

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Study Details

Description:

This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

Contacts:

Clinical Trials

clinicaltrials@fusionpharma.com

1 (888) 506-4215

Inclusion
  • Histologically or cytologically confirmed solid tumor prostrate metastatically/locally advamced PDAC CRC,NED
  • disease that has progressed despite prior treatment and for which additional effective standard therapy is not available
  • sufficient target expression at least 1 measurable lesion finding by Imaging following injection of In-FPI-2058
  • Measurable disease per RECIST v1.1
  • Tumor tissue(either archival within last 24 month or fresh biopsy
Exclusion

Exclusion Criteria Not Yet Provided

Patient Education

Patient Education Not Yet Provided

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468